FRISCO, Texas –(BUSINESS WIRE)–Soleo Healthan innovative leader and national provider of complex specialty pharmacy services, announced today that it has been selected as one of several specialty pharmacies selected to offer The Cover® for patients nationwide.
Administered subcutaneously, Cuvitru is produced by Takeda Pharmaceutical Company Ltd. Cuvitru replaces antibodies that don’t work properly or are missing from the body to help protect it against infection. CUVITRU is for the treatment of primary immunodeficiency (PI) in adults and children two years of age and older.
“Access to Cuvitru completes Soleo Health’s comprehensive immunoglobulin (Ig) therapy offering. With this addition, Soleo Health now offers all FDA-approved Ig therapies available on the market today. We continue to cater to the needs of our patients and prescribers by expanding our therapeutic portfolio and providing exceptional care,” noted Drew Walk, Chief Executive Officer of Soleo Health.
About Soleo Health
Soleo Health is an innovative national provider of complex specialty pharmacy services administered at home or in alternative care settings. Soleo Health’s interdisciplinary clinical team consists of experienced pharmacists, registered nurses, reimbursement specialists and patient care ambassadors. The company optimizes patient access solutions and provides comprehensive services, leading to measurable clinical and economic value, resulting in positive patient experiences.
Soleo Health works 21 locations across the US with national nursing coverage and pharmacy licensure in 50 states and is accredited by URAC, ACHC with distinction in rare diseases and orphan drugs, and The Joint Commission.